Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials - PubMed

Affiliations

• PMID: 25407702
• DOI: 10.1002/jbmr.2410

Free article

Meta-Analysis

Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials

Jannie D Hald et al. J Bone Miner Res. 2015 May.

Free article

Abstract

Bisphosphonates are widely used off-label in the treatment of patients with osteogenesis imperfecta (OI) with the intention of reducing the risk of fracture. Although there is strong evidence that bisphosphonates increase bone mineral density in osteogenesis imperfecta, the effects on fracture occurrence have been inconsistent. The aim of this study was to gain a better insight into the effects of bisphosphonate therapy on fracture risk in patients with osteogenesis imperfecta by conducting a meta-analysis of randomized controlled trials in which fractures were a reported endpoint. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials in which the effects of bisphosphonates on fracture risk in osteogenesis imperfecta were compared with placebo and conducted a meta-analysis of these studies using standard methods. Heterogeneity was assessed using the I2 statistic. Six eligible studies were identified involving 424 subjects with 751 patient-years of follow-up. The proportion of patients who experienced a fracture was not significantly reduced by bisphosphonate therapy (Relative Risk [RR] = 0.83 [95% confidence interval 0.69-1.01], p = 0.06) with no heterogeneity between studies (I2 = 0). The fracture rate was reduced by bisphosphonate treatment when all studies were considered (RR = 0.71 [0.52-0.96], p = 0.02), but with considerable heterogeneity (I2 = 36%) explained by one study where a small number of patients in the placebo group experienced a large number of fractures. When this study was excluded, the effects of bisphosphonates on fracture rate was not significant (RR = 0.79 [0.61-1.02], p = 0.07, I2 = 0%). We conclude that the effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive. Adequately powered trials with a fracture endpoint are needed to further investigate the risks and benefits of bisphosphonates in this condition.

Keywords: BISPHOSPHONATES; FRACTURE RISK; OSTEOGENESIS IMPERFECTA.

Similar articles

• Bisphosphonate therapy for osteogenesis imperfecta.

  Dwan K, Phillipi CA, Steiner RD, Basel D. Dwan K, et al. Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3. Cochrane Database Syst Rev. 2014. PMID: 25054949 Updated. Review.

• Bisphosphonate therapy for osteogenesis imperfecta.

  Dwan K, Phillipi CA, Steiner RD, Basel D. Dwan K, et al. Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.

• Bisphosphonate therapy for osteogenesis imperfecta.

  Phillipi CA, Remmington T, Steiner RD. Phillipi CA, et al. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005088. doi: 10.1002/14651858.CD005088.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843680 Updated. Review.

• Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.

  Ying ZM, Hu B, Yan SG. Ying ZM, et al. Orthop Surg. 2020 Aug;12(4):1293-1303. doi: 10.1111/os.12611. Epub 2020 Jun 26. Orthop Surg. 2020. PMID: 32589343 Free PMC article.

Cited by

• Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

  Glorieux FH, Langdahl B, Chapurlat R, De Beur SJ, Sutton VR, Poole KES, Dahir KM, Orwoll ES, Willie BM, Mikolajewicz N, Zimmermann E, Hosseinitabatabaei S, Ominsky MS, Saville C, Clancy J, MacKinnon A, Mistry A, Javaid MK. Glorieux FH, et al. J Bone Miner Res. 2024 Sep 2;39(9):1215-1228. doi: 10.1093/jbmr/zjae112. J Bone Miner Res. 2024. PMID: 39012717 Free PMC article. Clinical Trial.

• A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.

  Surowiec RK, Battle LF, Ward FS, Schlecht SH, Khoury BM, Robbins C, Wojtys EM, Caird MS, Kozloff KM. Surowiec RK, et al. Bone. 2020 Jan;130:115118. doi: 10.1016/j.bone.2019.115118. Epub 2019 Oct 31. Bone. 2020. PMID: 31678490 Free PMC article.

• Emerging Landscape of Osteogenesis Imperfecta Pathogenesis and Therapeutic Approaches.

  Sun Y, Li L, Wang J, Liu H, Wang H. Sun Y, et al. ACS Pharmacol Transl Sci. 2024 Jan 2;7(1):72-96. doi: 10.1021/acsptsci.3c00324. eCollection 2024 Jan 12. ACS Pharmacol Transl Sci. 2024. PMID: 38230285 Free PMC article. Review.

• Bisphosphonate Treatment Alters the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta: A Pilot Study.

  Sithambaran S, Harrison R, Gopal-Kothandapandi S, Rigby A, Bishop N. Sithambaran S, et al. JBMR Plus. 2022 Mar 1;6(3):e10592. doi: 10.1002/jbm4.10592. eCollection 2022 Mar. JBMR Plus. 2022. PMID: 35309861 Free PMC article. Clinical Trial.

• Finite element analysis of bone strength in osteogenesis imperfecta.

  Varga P, Willie BM, Stephan C, Kozloff KM, Zysset PK. Varga P, et al. Bone. 2020 Apr;133:115250. doi: 10.1016/j.bone.2020.115250. Epub 2020 Jan 22. Bone. 2020. PMID: 31981754 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems
  • Wiley

• Other Literature Sources

  • H1 Connect
  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information